Haemonetics Corp HAE

Health CareHealthcare Equipment & SuppliesUnited States of America

Last close 120.14 USD on Nov 2, 2026, +49.9% year to date

Quant rating

Quant rating A Rank 60 of 565 in Health Care

Growth B 212 of 565
Valuation D 521 of 565
Quality B 95 of 565
Revisions B 139 of 565
Momentum A 30 of 565

Wall Street consensus Buy (1.73)Average target 142.78 USD +18.8%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 5.5B
Enterprise value: 6.4B
52-week range: 49.32 – 123.63
3-year range: 47.67 – 123.63
Dividend yield: –
Beta (5 years): 0.59
Shares outstanding: 45.5M
Next earnings: Nov 5, 2026

About the company

Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.

Growth and profitability fiscal year ends March 31

Growth and profitability by fiscal year
	2026	2025	2024	2023	2022	5Y avg
Revenue (mil)	1,334	1,361	1,309	1,169	993	–
Revenue growth	−2.0%	4.0%	12.0%	17.7%	14.1%	8.9%
EPS (basic, normalized)	4.96	4.57	3.96	3.03	2.58	–
EPS growth	8.5%	15.4%	30.7%	17.4%	–	–
Gross margin	59.0%	56.1%	54.1%	53.3%	53.4%	55.2%
Net margin	7.3%	12.3%	9.0%	9.9%	4.4%	8.6%
ROE	12.0%	18.8%	13.2%	14.7%	5.9%	12.9%

Balance sheet, last quarter
Cash & short-term investments (mil)	223
Current ratio	3.08x
Long-term debt (mil)	1,169
Net debt (mil)	951
Total equity (mil)	837
Net debt / equity	1.14x
Net debt / EBITDA	2.11x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2026 actual	1,334	−2.0%	4.8x	450	+5.3%	14.3x	4.96	+8.5%	24.2x
2027	1,418	+6.3%	4.5x	429	−4.6%	14.9x	5.31	+7.1%	22.6x
2028	1,501	+5.9%	4.3x	465	+8.3%	13.8x	5.82	+9.5%	20.7x
2029	1,618	+7.8%	4.0x	496	+6.8%	12.9x	6.65	+14.2%	18.1x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2027	1,418	+0.1%	+1.1%	+1.7%	5.31	+0.1%	+1.8%	+0.4%
2028	1,501	+0.4%	+1.8%	+1.2%	5.82	+0.7%	+1.8%	−1.7%
2029	1,618	+1.2%	+3.4%	–	6.65	+2.1%	+6.2%	–

Earnings surprises EPS beat in 4 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	343	336	346	349	331	321	327	339	346	339
Sales mean (mil)	329	335	343	353	329	304	311	332	337	328
Surprise	+4.3%	+0.2%	+0.8%	−1.2%	+0.4%	+5.6%	+5.1%	+2.2%	+2.8%	+3.5%
EPS reported	0.90	1.02	1.12	1.19	1.24	1.10	1.27	1.31	1.29	1.14
EPS mean	0.89	1.01	1.07	1.17	1.22	1.02	1.11	1.25	1.27	1.08
Surprise	+1.0%	+1.4%	+4.4%	+1.7%	+1.6%	+8.3%	+14.4%	+4.8%	+1.4%	+5.9%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
HAE Haemonetics Corp	5.5B	2.11x	7.3%	6.53x	22.6x	20.7x	14.9x	13.8x
ABT Abbott Laboratories	190.6B	2.36x	14.7%	3.73x	20.0x	18.6x	16.5x	15.0x
ISRG Intuitive Surgical, Inc.	151.4B	−0.91x	28.4%	9.47x	38.8x	35.0x	26.4x	24.3x
MDT Medtronic PLC	127.0B	1.99x	13.2%	2.53x	16.6x	15.5x	13.2x	12.6x
SYK Stryker Corporation	116.8B	1.65x	12.9%	4.98x	20.7x	18.8x	16.4x	15.3x
BSX Boston Scientific Corporation	64.2B	2.03x	14.4%	2.57x	14.0x	14.2x	12.1x	12.1x
Mean		1.54x	15.2%	4.97x	22.1x	20.5x	16.6x	15.5x
Median		2.01x	13.8%	4.35x	20.3x	18.7x	15.7x	14.4x

Technical analysis

1M+14.8%
3M+40.4%
1Y+140.2%
3Y+40.6%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Haemonetics Corp, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Total revenue	1,334	1,361	1,309	1,169	993	870
Cost of revenue	547	597	600	546	462	463
Gross profit	787	764	709	623	531	408
Selling, general & administrative expenses	436	409	411	374	332	269
Research & development	58.8	61.1	52.2	49.1	46.0	31.7
Depreciation/amortization	44.0	48.3	32.0	32.6	47.4	32.8
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	91.1	23.4	48.4	11.4	25.0	−16.1
Other operating expenses	0	0	0	0	0	0
Operating income	157	222	165	156	80.8	89.7
Net interest income (expense)	−28.7	−9.7	−13.0	−14.6	−17.1	−16.8
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	128	212	152	141	63.6	72.9
Provision for taxes	30.7	44.4	34.3	26.0	20.3	−6.6
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	97.3	168	118	115	43.4	79.5
Extraordinary items	–	–	–	–	–	–
Net income	97.3	168	118	115	43.4	79.5
EBIT, normalized	289	265	236	187	140	97.1
EBITDA, normalized	400	381	333	280	241	181
Basic EPS, normalized	4.96	4.57	3.96	3.03	2.58	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Haemonetics Corp, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Assets
Cash & short-term investments	245	307	179	284	259	192
Receivables	217	203	207	179	159	128
Total inventory	306	365	317	259	293	323
Prepaid expenses	66.2	60.4	66.3	46.7	44.1	51.1
Other current assets	0	0	0	0	0	0
Total current assets	835	935	769	770	756	694
Property, plant & equipment	345	332	367	364	311	277
Goodwill	656	604	565	466	467	466
Intangibles	448	456	406	276	310	365
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	112	124	88.9	58.8	14.9	17.0
Total assets	2,396	2,451	2,196	1,935	1,860	1,820
Liabilities
Accounts payable	51.1	67.0	73.4	63.9	58.4	50.3
Payable/accrued	–	–	–	–	–	–
Accrued expenses	77.4	67.5	88.8	71.6	66.0	79.0
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	5.0	304	10.2	11.8	214	17.0
Other current liabilities	149	140	128	104	104	107
Total current liabilities	283	578	300	252	442	253
Long-term debt	1,220	921	798	754	559	691
Minority interest	–	–	–	–	–	–
Other liabilities	97.4	131	138	111	109	144
Total liabilities	1,600	1,630	1,236	1,117	1,110	1,088
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.5	0.5	0.5	0.5	0.5	0.5
Additional paid-in capital	554	523	635	595	572	603
Retained earnings (accumulated deficit)	279	352	360	253	202	158
Treasury stock	–	–	–	–	–	–
Other equity	−37.6	−55.1	−35.6	−30.4	−26.0	−29.5
Total equity	796	821	960	818	749	732
Total liabilities & shareholders' equity	2,396	2,451	2,196	1,935	1,860	1,820

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Haemonetics Corp, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Operating activities
Net income	97.3	168	118	115	43.4	79.5
Depreciation, depletion & amortization	112	116	97.2	93.3	97.7	84.3
Deferred taxes	−26.5	−5.2	−11.0	4.8	5.0	−19.9
Non-cash items	134	5.6	52.7	34.1	41.3	24.6
Changes in working capital	−23.7	−102	−74.7	25.5	−15.2	−59.7
Cash from operations	293	182	182	273	172	109
Investing activities
Capital expenditures	−84.7	−60.4	−66.3	−110	−96.5	−37.0
Other investing cash flows	−94.9	−102	−256	−33.6	10.2	−388
Cash from investing	−180	−162	−322	−144	−86.3	−425
Financing activities
Financing cash flow items	−5.1	−122	−6.8	−22.8	−4.8	−60.9
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−173	231	45.0	−77.6	−11.0	428
Cash from financing	−178	109	38.2	−100	−15.7	367
Foreign exchange effects	3.5	−0.7	−3.2	−3.9	−3.0	4.2
Net change in cash	−61.3	128	−106	25.0	67.2	55.0
Free cash flow	209	121	115	163	75.8	71.8

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.